

Myeloproliferative Disorders Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

<https://marketpublishers.com/r/MC6524431E57EN.html>

Date: May 2025

Pages: 100

Price: US\$ 3,200.00 (Single User License)

ID: MC6524431E57EN

Abstracts

Myeloproliferative Disorders Drugs Market Summary

Introduction and Market Overview

Myeloproliferative disorders (MPD) drugs, including JAK inhibitors, tyrosine kinase inhibitors (TKIs), interferons, and others, treat conditions like chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis, with 20,000 new U.S. cases annually. The market is driven by an aging population (1 billion over 60 in 2020, projected to reach 2.1 billion by 2050), with PV and ET incidence at 2-3 per 100,000 in those over 65. Novel therapies like ruxolitinib (90% JAK2 mutation detection in PV) and FDA approvals, such as asciminib for CML in 2024, boost growth. Precision medicine improves efficacy by 30%. The global MPD drugs market is estimated at USD 6.0-11.0 billion in 2025, with a CAGR of 3%-8% through 2030.

Regional Market Trends

North America: The U.S. leads with high MPD prevalence and novel therapy adoption, while Canada emphasizes targeted treatments.

Europe: Germany, France, and the UK drive growth with advanced hematology care.

Asia Pacific: Japan and China see rising cases due to aging, with India focusing on generics.

Rest of the World: Brazil enhances oncology infrastructure, while the Middle East addresses rare diseases.

Application Analysis

Hospitals: Expected growth of 3.5%-8.5%, driven by acute MPD cases. Trends focus on specialized oncology units.

Specialty Clinics: Projected growth of 3.2%-8.2%, linked to chronic management. Advances emphasize outpatient care.

Others: Anticipated growth of 3.0%-8.0%, covering home care. Trends highlight patient support programs.

Type Analysis

JAK Inhibitors: Expected growth of 4.0%-9.0%, effective for myelofibrosis. Trends focus on ruxolitinib and fedratinib.

TKIs: Projected growth of 3.8%-8.8%, for CML treatment. Advances emphasize asciminib and imatinib generics.

IFNs: Anticipated growth of 3.5%-8.5%, used in PV and ET. Trends highlight long-acting formulations.

Others: Expected growth of 3.2%-8.2%, covering emerging therapies. Developments prioritize precision medicine.

Key Market Players

Novartis: Offers asciminib and imatinib for CML.

Bristol-Myers Squibb: Develops TKIs for MPD treatment.

Pfizer: Provides supportive MPD therapies.

Incyte: Pioneers ruxolitinib for myelofibrosis.

GSK: Supplies momelotinib for myelofibrosis.

Porter's Five Forces Analysis

Threat of New Entrants: Low, due to high R&D costs and orphan drug regulations.

Threat of Substitutes: Low, as targeted therapies are essential, with few alternatives.

Bargaining Power of Buyers: Moderate, as insurers negotiate prices, but limited options strengthen providers.

Bargaining Power of Suppliers: Low, with multiple suppliers of active ingredients.

Competitive Rivalry: High, with companies competing on efficacy, safety, and speed to market.

Market Opportunities and Challenges

Opportunities:

Addressing 20,000 new U.S. MPD cases annually.

Targeting an aging population, with 2-3/100,000 PV and ET incidence.

Leveraging JAK inhibitors, with 90% JAK2 mutation detection.

Utilizing precision medicine, improving efficacy by 30%.

Benefiting from FDA orphan drug approvals.

Expanding targeted therapies for rare MPDs.

Challenges:

High costs of novel therapies limiting access.

Regulatory delays for pipeline drugs.

Limited MPD awareness in developing regions.

Side effects of JAK inhibitors requiring monitoring.

Competition from supportive care options.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 ABBREVIATION AND ACRONYMS

CHAPTER 3 PREFACE

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter Four Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End Users

CHAPTER 5 MARKET TREND ANALYSIS

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

CHAPTER 6 INDUSTRY CHAIN ANALYSIS

6.1 Upstream/Suppliers Analysis

6.2 Myeloproliferative Disorders Drug Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End Users

CHAPTER 7 LATEST MARKET DYNAMICS

7.1 Latest News

7.2 Merger and Acquisition

7.3 Planned/Future Project

7.4 Policy Dynamics

CHAPTER 8 HISTORICAL AND FORECAST MYELOPROLIFERATIVE DISORDERS DRUG MARKET IN NORTH AMERICA (2020-2030)

8.1 Myeloproliferative Disorders Drug Market Size

8.2 Myeloproliferative Disorders Drug Market by End Use

8.3 Competition by Players/Suppliers

8.4 Myeloproliferative Disorders Drug Market Size by Type

8.5 Key Countries Analysis

8.5.1 United States

8.5.2 Canada

8.5.3 Mexico

CHAPTER 9 HISTORICAL AND FORECAST MYELOPROLIFERATIVE DISORDERS DRUG MARKET IN SOUTH AMERICA (2020-2030)

9.1 Myeloproliferative Disorders Drug Market Size

9.2 Myeloproliferative Disorders Drug Market by End Use

9.3 Competition by Players/Suppliers

9.4 Myeloproliferative Disorders Drug Market Size by Type

9.5 Key Countries Analysis

9.5.1 Brazil

9.5.2 Argentina

9.5.3 Chile

9.5.4 Peru

CHAPTER 10 HISTORICAL AND FORECAST MYELOPROLIFERATIVE DISORDERS DRUG MARKET IN ASIA & PACIFIC (2020-2030)

10.1 Myeloproliferative Disorders Drug Market Size

10.2 Myeloproliferative Disorders Drug Market by End Use

10.3 Competition by Players/Suppliers

10.4 Myeloproliferative Disorders Drug Market Size by Type

10.5 Key Countries Analysis

10.5.1 China

10.5.2 India

10.5.3 Japan

- 10.5.4 South Korea
- 10.5.5 Southeast Asia
- 10.5.6 Australia

CHAPTER 11 HISTORICAL AND FORECAST MYELOPROLIFERATIVE DISORDERS DRUG MARKET IN EUROPE (2020-2030)

- 11.1 Myeloproliferative Disorders Drug Market Size
- 11.2 Myeloproliferative Disorders Drug Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Myeloproliferative Disorders Drug Market Size by Type
- 11.5 Key Countries Analysis
 - 11.5.1 Germany
 - 11.5.2 France
 - 11.5.3 United Kingdom
 - 11.5.4 Italy
 - 11.5.5 Spain
 - 11.5.6 Belgium
 - 11.5.7 Netherlands
 - 11.5.8 Austria
 - 11.5.9 Poland
 - 11.5.10 Russia

CHAPTER 12 HISTORICAL AND FORECAST MYELOPROLIFERATIVE DISORDERS DRUG MARKET IN MEA (2020-2030)

- 12.1 Myeloproliferative Disorders Drug Market Size
- 12.2 Myeloproliferative Disorders Drug Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Myeloproliferative Disorders Drug Market Size by Type
- 12.5 Key Countries Analysis
 - 12.5.1 Egypt
 - 12.5.2 Israel
 - 12.5.3 South Africa
 - 12.5.4 Gulf Cooperation Council Countries
 - 12.5.5 Turkey

CHAPTER 13 SUMMARY FOR GLOBAL MYELOPROLIFERATIVE DISORDERS DRUG MARKET (2020-2025)

- 13.1 Myeloproliferative Disorders Drug Market Size
- 13.2 Myeloproliferative Disorders Drug Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Myeloproliferative Disorders Drug Market Size by Type

CHAPTER 14 GLOBAL MYELOPROLIFERATIVE DISORDERS DRUG MARKET FORECAST (2025-2030)

- 14.1 Myeloproliferative Disorders Drug Market Size Forecast
- 14.2 Myeloproliferative Disorders Drug Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Myeloproliferative Disorders Drug Type Forecast

CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS

- 15.1 Novartis
 - 15.1.1 Company Profile
 - 15.1.2 Main Business and Myeloproliferative Disorders Drug Information
 - 15.1.3 SWOT Analysis of Novartis
 - 15.1.4 Novartis Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
- 15.2 Bristol-Myers Squibb
 - 15.2.1 Company Profile
 - 15.2.2 Main Business and Myeloproliferative Disorders Drug Information
 - 15.2.3 SWOT Analysis of Bristol-Myers Squibb
 - 15.2.4 Bristol-Myers Squibb Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
- 15.3 Pfizer
 - 15.3.1 Company Profile
 - 15.3.2 Main Business and Myeloproliferative Disorders Drug Information
 - 15.3.3 SWOT Analysis of Pfizer
 - 15.3.4 Pfizer Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)
- 15.4 Incyte
 - 15.4.1 Company Profile
 - 15.4.2 Main Business and Myeloproliferative Disorders Drug Information
 - 15.4.3 SWOT Analysis of Incyte
 - 15.4.4 Incyte Myeloproliferative Disorders Drug Revenue, Gross Margin and Market

Share (2020-2025)

15.5 GSK

15.5.1 Company Profile

15.5.2 Main Business and Myeloproliferative Disorders Drug Information

15.5.3 SWOT Analysis of GSK

15.5.4 GSK Myeloproliferative Disorders Drug Revenue, Gross Margin and Market

Share (2020-2025)

15.6 Eli Lilly

15.6.1 Company Profile

15.6.2 Main Business and Myeloproliferative Disorders Drug Information

15.6.3 SWOT Analysis of Eli Lilly

15.6.4 Eli Lilly Myeloproliferative Disorders Drug Revenue, Gross Margin and Market

Share (2020-2025)

15.7 Takeda Pharmaceutical

15.7.1 Company Profile

15.7.2 Main Business and Myeloproliferative Disorders Drug Information

15.7.3 SWOT Analysis of Takeda Pharmaceutical

15.7.4 Takeda Pharmaceutical Myeloproliferative Disorders Drug Revenue, Gross

Margin and Market Share (2020-2025)

15.8 Teva Pharmaceutical

15.8.1 Company Profile

15.8.2 Main Business and Myeloproliferative Disorders Drug Information

15.8.3 SWOT Analysis of Teva Pharmaceutical

15.8.4 Teva Pharmaceutical Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)

15.9 AbbVie

15.9.1 Company Profile

15.9.2 Main Business and Myeloproliferative Disorders Drug Information

15.9.3 SWOT Analysis of AbbVie

15.9.4 AbbVie Myeloproliferative Disorders Drug Revenue, Gross Margin and Market Share (2020-2025)

Please ask for sample pages for full companies list

Tables and Figures

Table Abbreviation and Acronyms

Table Research Scope of Myeloproliferative Disorders Drug Report

Table Data Sources of Myeloproliferative Disorders Drug Report

Table Major Assumptions of Myeloproliferative Disorders Drug Report

Figure Market Size Estimated Method

Figure Major Forecasting Factors

Figure Myeloproliferative Disorders Drug Picture

Table Myeloproliferative Disorders Drug Classification

Table Myeloproliferative Disorders Drug Applications

Table Drivers of Myeloproliferative Disorders Drug Market

Table Restraints of Myeloproliferative Disorders Drug Market

Table Opportunities of Myeloproliferative Disorders Drug Market

Table Threats of Myeloproliferative Disorders Drug Market

Table Covid-19 Impact For Myeloproliferative Disorders Drug Market

Table Raw Materials Suppliers

Table Different Production Methods of Myeloproliferative Disorders Drug

Table Cost Structure Analysis of Myeloproliferative Disorders Drug

Table Key End Users

Table Latest News of Myeloproliferative Disorders Drug Market

Table Merger and Acquisition

Table Planned/Future Project of Myeloproliferative Disorders Drug Market

Table Policy of Myeloproliferative Disorders Drug Market

Table 2020-2030 North America Myeloproliferative Disorders Drug Market Size

Figure 2020-2030 North America Myeloproliferative Disorders Drug Market Size and CAGR

Table 2020-2030 North America Myeloproliferative Disorders Drug Market Size by Application

Table 2020-2025 North America Myeloproliferative Disorders Drug Key Players Revenue

Table 2020-2025 North America Myeloproliferative Disorders Drug Key Players Market Share

Table 2020-2030 North America Myeloproliferative Disorders Drug Market Size by Type

Table 2020-2030 United States Myeloproliferative Disorders Drug Market Size

Table 2020-2030 Canada Myeloproliferative Disorders Drug Market Size

Table 2020-2030 Mexico Myeloproliferative Disorders Drug Market Size

Table 2020-2030 South America Myeloproliferative Disorders Drug Market Size

Figure 2020-2030 South America Myeloproliferative Disorders Drug Market Size and CAGR

Table 2020-2030 South America Myeloproliferative Disorders Drug Market Size by Application

Table 2020-2025 South America Myeloproliferative Disorders Drug Key Players Revenue

Table 2020-2025 South America Myeloproliferative Disorders Drug Key Players Market Share

Table 2020-2030 South America Myeloproliferative Disorders Drug Market Size by Type

Table 2020-2030 Brazil Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Argentina Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Chile Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Peru Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Asia & Pacific Myeloproliferative Disorders Drug Market Size
Figure 2020-2030 Asia & Pacific Myeloproliferative Disorders Drug Market Size and CAGR
Table 2020-2030 Asia & Pacific Myeloproliferative Disorders Drug Market Size by Application
Table 2020-2025 Asia & Pacific Myeloproliferative Disorders Drug Key Players Revenue
Table 2020-2025 Asia & Pacific Myeloproliferative Disorders Drug Key Players Market Share
Table 2020-2030 Asia & Pacific Myeloproliferative Disorders Drug Market Size by Type
Table 2020-2030 China Myeloproliferative Disorders Drug Market Size
Table 2020-2030 India Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Japan Myeloproliferative Disorders Drug Market Size
Table 2020-2030 South Korea Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Southeast Asia Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Australia Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Europe Myeloproliferative Disorders Drug Market Size
Figure 2020-2030 Europe Myeloproliferative Disorders Drug Market Size and CAGR
Table 2020-2030 Europe Myeloproliferative Disorders Drug Market Size by Application
Table 2020-2025 Europe Myeloproliferative Disorders Drug Key Players Revenue
Table 2020-2025 Europe Myeloproliferative Disorders Drug Key Players Market Share
Table 2020-2030 Europe Myeloproliferative Disorders Drug Market Size by Type
Table 2020-2030 Germany Myeloproliferative Disorders Drug Market Size
Table 2020-2030 France Myeloproliferative Disorders Drug Market Size
Table 2020-2030 United Kingdom Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Italy Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Spain Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Belgium Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Netherlands Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Austria Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Poland Myeloproliferative Disorders Drug Market Size
Table 2020-2030 Russia Myeloproliferative Disorders Drug Market Size
Table 2020-2030 MEA Myeloproliferative Disorders Drug Market Size
Figure 2020-2030 MEA Myeloproliferative Disorders Drug Market Size and CAGR
Table 2020-2030 MEA Myeloproliferative Disorders Drug Market Size by Application
Table 2020-2025 MEA Myeloproliferative Disorders Drug Key Players Revenue

Table 2020-2025 MEA Myeloproliferative Disorders Drug Key Players Market Share

Table 2020-2030 MEA Myeloproliferative Disorders Drug Market Size by Type

Table 2020-2030 Egypt Myeloproliferative Disorders Drug Market Size

Table 2020-2030 Israel Myeloproliferative Disorders Drug Market Size

Table 2020-2030 South Africa Myeloproliferative Disorders Drug Market Size

Table 2020-2030 Gulf Cooperation Council Countries Myeloproliferative Disorders Drug Market Size

Table 2020-2030 Turkey Myeloproliferative Disorders Drug Market Size

Table 2020-2025 Global Myeloproliferative Disorders Drug Market Size by Region

Table 2020-2025 Global Myeloproliferative Disorders Drug Market Size Share by Region

Table 2020-2025 Global Myeloproliferative Disorders Drug Market Size by Application

Table 2020-2025 Global Myeloproliferative Disorders Drug Market Share by Application

Table 2020-2025 Global Myeloproliferative Disorders Drug Key Vendors Revenue

Figure 2020-2025 Global Myeloproliferative Disorders Drug Market Size and Growth Rate

Table 2020-2025 Global Myeloproliferative Disorders Drug Key Vendors Market Share

Table 2020-2025 Global Myeloproliferative Disorders Drug Market Size by Type

Table 2020-2025 Global Myeloproliferative Disorders Drug Market Share by Type

Table 2025-2030 Global Myeloproliferative Disorders Drug Market Size by Region

Table 2025-2030 Global Myeloproliferative Disorders Drug Market Size Share by Region

Table 2025-2030 Global Myeloproliferative Disorders Drug Market Size by Application

Table 2025-2030 Global Myeloproliferative Disorders Drug Market Share by Application

Table 2025-2030 Global Myeloproliferative Disorders Drug Key Vendors Revenue

Figure 2025-2030 Global Myeloproliferative Disorders Drug Market Size and Growth Rate

Table 2025-2030 Global Myeloproliferative Disorders Drug Key Vendors Market Share

Table 2025-2030 Global Myeloproliferative Disorders Drug Market Size by Type

Table 2025-2030 Myeloproliferative Disorders Drug Global Market Share by Type

I would like to order

Product name: Myeloproliferative Disorders Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

Product link: <https://marketpublishers.com/r/MC6524431E57EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MC6524431E57EN.html>